Pretomanid is being tested as Element of a combination program like moxifloxacin and PZA for your treatment of the two drug-susceptible and drug-resistant tuberculosis (ClinicalTrials.gov identifier: NCT02193776). Bedaquiline, accredited because of the US FDA for treatment of multidrug-resistant tuberculosis in 2012, can also be being investigated